Safety and Systemic Exposure of Triamcinolone Acetonide Following Ultrasound-Guided Intra-Articular Injection of Triamcinolone Extended-Release or Standard Triamcinolone Acetonide in Patients with Shoulder Osteoarthritis: An Open-Label, Randomized Study.
Journal
Drugs in R&D
ISSN: 1179-6901
Titre abrégé: Drugs R D
Pays: New Zealand
ID NLM: 100883647
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
accepted:
11
05
2021
pubmed:
6
8
2021
medline:
26
10
2021
entrez:
5
8
2021
Statut:
ppublish
Résumé
Osteoarthritis (OA) is a major public health burden. While knee and hip joints are most commonly affected, the glenohumoral (shoulder) joint is also frequently involved. We evaluated the pharmacokinetics and safety/tolerability of triamcinolone acetonide extended-release (TA-ER) and triamcinolone acetonide crystalline suspension (TAcs) in patients with shoulder OA. In this phase 2, randomized, open-label, single-dose study (NCT03382262), adults with moderately-to-severely symptomatic shoulder OA for ≥ 6 months randomly received a single ultrasound-guided intra-articular (IA) injection of TA-ER 32 mg or TAcs 40 mg. Safety was evaluated throughout 12 weeks post-injection; blood samples for pharmacokinetic evaluations were collected pre-injection and through Day 85 post-injection. Among 25 randomized patients, 12 received TA-ER and 13 received TAcs. Most patients were female (60%), and all had moderate (72%) or severe (28%) shoulder OA. Adverse events (AEs) were reported by four (33%) patients following TA-ER and three (23%) following TAcs injection. No AE was serious or led to study discontinuation. Systemic exposure following TAcs was approximately 1.5-fold higher than that following TA-ER injection (geometric mean [GM] AUC These pharmacokinetic data confirm protracted release of TA from TA-ER following IA injection in patients with shoulder OA. Lower peak and systemic TA exposure following TA-ER suggests TA-ER could potentially confer an improved systemic safety profile over TAcs. NCT03382262 (December 22, 2017 retrospectively registered).
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
Osteoarthritis (OA) is a major public health burden. While knee and hip joints are most commonly affected, the glenohumoral (shoulder) joint is also frequently involved. We evaluated the pharmacokinetics and safety/tolerability of triamcinolone acetonide extended-release (TA-ER) and triamcinolone acetonide crystalline suspension (TAcs) in patients with shoulder OA.
METHODS
METHODS
In this phase 2, randomized, open-label, single-dose study (NCT03382262), adults with moderately-to-severely symptomatic shoulder OA for ≥ 6 months randomly received a single ultrasound-guided intra-articular (IA) injection of TA-ER 32 mg or TAcs 40 mg. Safety was evaluated throughout 12 weeks post-injection; blood samples for pharmacokinetic evaluations were collected pre-injection and through Day 85 post-injection.
RESULTS
RESULTS
Among 25 randomized patients, 12 received TA-ER and 13 received TAcs. Most patients were female (60%), and all had moderate (72%) or severe (28%) shoulder OA. Adverse events (AEs) were reported by four (33%) patients following TA-ER and three (23%) following TAcs injection. No AE was serious or led to study discontinuation. Systemic exposure following TAcs was approximately 1.5-fold higher than that following TA-ER injection (geometric mean [GM] AUC
CONCLUSION
CONCLUSIONS
These pharmacokinetic data confirm protracted release of TA from TA-ER following IA injection in patients with shoulder OA. Lower peak and systemic TA exposure following TA-ER suggests TA-ER could potentially confer an improved systemic safety profile over TAcs.
TRIAL REGISTRATION NUMBER
BACKGROUND
NCT03382262 (December 22, 2017 retrospectively registered).
Identifiants
pubmed: 34350546
doi: 10.1007/s40268-021-00348-1
pii: 10.1007/s40268-021-00348-1
pmc: PMC8363704
doi:
Substances chimiques
Delayed-Action Preparations
0
Triamcinolone Acetonide
F446C597KA
Banques de données
ClinicalTrials.gov
['NCT03382262']
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
285-293Informations de copyright
© 2021. The Author(s).
Références
J Bone Joint Surg Am. 2015 Jun 3;97(11):877-88
pubmed: 26041848
Lancet. 2019 Apr 27;393(10182):1745-1759
pubmed: 31034380
JAMA. 2018 Mar 6;319(9):872-882
pubmed: 29509867
J Bone Joint Surg Am. 2018 Apr 18;100(8):666-677
pubmed: 29664853
J Shoulder Elbow Surg. 2013 Aug;22(8):1063-7
pubmed: 23375877
J Shoulder Elbow Surg. 2014 May;23(5):613-9
pubmed: 24561177
J Am Acad Orthop Surg. 2013 Sep;21(9):571-6
pubmed: 23996988
Clin Geriatr Med. 2010 Aug;26(3):355-69
pubmed: 20699159
Expert Opin Drug Metab Toxicol. 2019 Dec;15(12):1021-1032
pubmed: 31709838
Int J Pharm. 2020 Apr 15;579:119130
pubmed: 32070759
J Shoulder Elbow Surg. 2011 Jul;20(5):756-63
pubmed: 21530320
Arthritis Rheumatol. 2018 Feb;70(2):204-211
pubmed: 29088579
Orthop Res Rev. 2018 Feb 23;10:9-18
pubmed: 30774456
Osteoarthritis Cartilage. 2018 Jan;26(1):34-42
pubmed: 29024802
Rheumatology (Oxford). 2018 Dec 1;57(12):2235-2241
pubmed: 30203101
Rheumatol Ther. 2019 Mar;6(1):109-124
pubmed: 30741382